Biotech Stocks in Motion - Amgen, Merrimack Pharma, NPS Pharma, BioMarin Pharma, and Regeneron Pharma

Editor Note: For more information about this release, please scroll to bottom.

LONDON, November 24, 2014 /PRNewswire/ --

Investor-Edge has initiated coverage on the following equities: Amgen Inc. (NASDAQ: AMGN), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), NPS Pharmaceuticals Inc. (NASDAQ: NPSP), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, November 21, 2014, the NASDAQ Composite ended at 4,712.97, up 0.24%, the Dow Jones Industrial Average advanced 0.51%, to finish the day at 17,810.06, and the S&P 500 closed at 2,063.50, up 0.52%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 789.16, up 0.39%, with the index also advancing 8.50% in the last three months. Register for your complimentary reports on these five stocks at:  

http://investor-edge.com/register

On Friday, shares in Amgen Inc. recorded a trading volume of 3.72 million shares, lower than its three months average volume of 3.93 million shares. The stock ended the day at $162.81, which was 0.08% above its previous day's closing of $162.68, and registered an intraday range of $161.43 and $165.58. Shares of the company traded at a PE ratio of 24.13. Amgen Inc.'s shares have surged 13.35% in the last one month, 22.58% in the previous three months and 42.72% on YTD basis. The company's stock is trading above its 50-day and 200-day moving averages of $147.60 and $128.33, respectively. Furthermore, shares of Amgen Inc. have a Relative Strength Index (RSI) of 67.44. Sign up and read the free notes on AMGN at:

www.Investor-Edge.com/AMGN-24Nov2014

Merrimack Pharmaceuticals Inc.'s stock edged 0.77% lower, to close Friday's session at $9.03, after oscillating between $8.95 and $9.26. The stock recorded a trading volume of 2.00 million shares, below its three months average volume of 2.20 million shares. Over the last one month and the previous three months, Merrimack Pharmaceuticals Inc.'s shares have advanced 7.50% and 37.03%, respectively. Additionally, from the beginning of 2014, the stock has gained an upside of 69.39%. The company's stock is trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $8.41 is above its 200-day moving average of $6.77. Further, Merrimack Pharmaceuticals Inc.'s stock has an RSI of 56.19. The complimentary notes on MACK can be downloaded as in PDF format at:

www.Investor-Edge.com/MACK-24Nov2014

NPS Pharmaceuticals Inc.'s stock finished Friday's session 1.27% higher at $32.00. A total of 1.87 million shares were traded, which was below its three months average volume of 2.14 million shares. The stock moved between $31.29 and $32.15 during the session. NPS Pharmaceuticals Inc.'s shares have surged 15.69% in the last one month and 17.47% in the previous three months. Additionally, the stock has gained 5.40% on YTD basis. The company's shares are trading above their 50-day and 200-day moving averages. Moreover, the stock's 200-day moving average of $29.43 is greater than its 50-day moving average of $27.11. NPS Pharmaceuticals Inc.'s stock traded at a PE ratio of 4940.56 and has an RSI of 66.68. Register for free on Investor-Edge and access the latest research on NPSP at:

www.Investor-Edge.com/NPSP-24Nov2014

On Friday, shares in BioMarin Pharmaceutical Inc. fluctuated between $84.26 and $86.34 before ending the session 1.66% higher at $85.83. The stock reported a trading volume of 0.85 million shares, below its three months average volume of 1.10 million shares. BioMarin Pharmaceutical Inc.'s shares have gained 15.49% in the last one month, 22.33% in the previous three months and 22.00% on YTD basis. The company's stock is trading above its 50-day and 200-day moving averages of $76.25 and $68.34, respectively. Moreover, shares of BioMarin Pharmaceutical Inc. have an RSI of 60.83. The complete research on BMRN is available for free at:

www.Investor-Edge.com/BMRN-24Nov2014

Regeneron Pharmaceuticals Inc.'s stock edged 0.18% lower, to close the day at $405.25. The stock recorded a trading volume of 0.89 million shares, above its three months average volume of 0.81million shares. The stock oscillated between $403.29 and $416.00 during the session. Over the last one month and over the past three months, Regeneron Pharmaceuticals Inc.'s shares have gained 5.41% and 18.91%, respectively. Further, the stock has surged 47.24% since the start of this year. The company's stock is trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $373.24 is above its 200-day moving average of $329.63. Additionally, Regeneron Pharmaceuticals Inc.'s stock traded at a PE ratio of 133.38 and has an RSI of 59.44. Free in depth research on REGN is available at:

www.Investor-Edge.com/REGN-24Nov2014

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Investor-Edge

Suggested Articles

With momentum building in Pfizer’s gene therapy programs, it has bought a building in North Carolina where it will consolidate clinical manufacturing.

Novo Nordisk had been hoping to show its Tresiba could top Sanofi’s Toujeo in a head-to-head showdown, but it didn't quite get there.

GlaxoSmithKline won an FDA panel recommendation for its over-the-counter nicotine spray—but the backing didn’t come easy.